Companies › Aminex Therapeutics
2 active drug programs in 9 registered trials: 5 Phase 2, 4 Phase 1; Oncology, Metabolic and endocrine; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AMXT 1501 Dicaprate Ornithine decarboxylase (ODC) inhibitor | ODC1 | Phase 1 | Melanoma (Skin Cancer); Atypical Teratoid/Rhabdoid Tumor | Feb 2028 |
| Eflornithine Hydrochloride Ornithine decarboxylase inhibitor | ODC1 | Phase 1 | Melanoma (Skin Cancer); Type 1 Diabetes; Neuroblastoma; Medulloblastoma … | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05594563 | Eflornithine Hydrochloride | Phase 2 | Type 1 Diabetes | Metabolic and endocrine | Jun 2027 |
| NCT02679144 | Eflornithine Hydrochloride | Phase 2 | Neuroblastoma | Oncology | Feb 2028 |
| NCT07287917 | AMXT 1501 Dicaprate | Phase 1 | Melanoma (Skin Cancer) | Oncology | Feb 2028 |
| NCT07287917 | Eflornithine Hydrochloride | Phase 1 | Melanoma (Skin Cancer) | Oncology | Feb 2028 |
| NCT04696029 | Eflornithine Hydrochloride | Phase 2 | Medulloblastoma | Oncology | Mar 2028 |
| NCT04301843 | Eflornithine Hydrochloride | Phase 2 | Neuroblastoma | Oncology | Oct 2028 |
| NCT06892678 | Eflornithine Hydrochloride | Phase 1 | Osteosarcoma Recurrent | Oncology | Apr 2030 |
| NCT02559778 | Eflornithine Hydrochloride | Phase 2 | Neuroblastoma | Oncology | Sep 2030 |
| NCT06465199 | AMXT 1501 Dicaprate | Phase 1 | Atypical Teratoid/Rhabdoid Tumor | Oncology | May 2033 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.